Chong Kun Dang’s Pregrel demonstrates comparable to Plavix

The safety and efficacy can be achieved for 300 patients exposing to a high risk of coronary artery disease or its similar disease with Chong Kun Dang’s Pregrel, the generic version of Plavix, a blockbuster blood-thinning drug from Sanofi and Bristol-Myers Squibb Co., new data presented recently has revealed.

The results, presented at the Korean Society of Cardiology in Seoul, showed that p...